Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#21
JOURNAL ARTICLE
Mayumi Ohtsuka, Tohru Yamaguchi, Sachiko Oishi, Koichi Misawa, Atsushi Suzuki, Masanobu Hibi, Masakazu Terauchi
Hormonal changes during the menopause transition may lead to vasomotor symptoms, including hot flashes (HFs) and neuropsychiatric symptoms such as anxiety and irritability. We hypothesized that the effects of cassis polyphenol (CaP) to improve microcirculation and vasorelaxation may alleviate menopausal symptoms. We performed a randomized, double-blind, parallel-group, placebo-controlled trial involving 59 healthy women (mean [standard deviation] age, 51.3 [4.3] years; body mass index, 20.8 [2.6] kg/m2 ). Participants experiencing subjective menopausal symptoms consumed CaP tablets (400 mg/d, CaP group) or placebo tablets (placebo group) for 4 weeks...
March 21, 2024: Nutrition Research
#22
JOURNAL ARTICLE
Alexis N Reeves, Tené T Lewis, Michelle M Hood, Rebecca C Thurston, Nancy E Avis, Sherri-Ann M Burnett-Bowie, Yamnia I Cortés, Genevieve Neal-Perry, Siobán D Harlow
OBJECTIVES: Vasomotor symptoms (VMS), including hot flashes and night sweats, are hallmark symptoms of the menopause transition. Previous research has documented greater frequency, duration, and severity of VMS in Black women compared with women from other racial/ethnic groups, even after accounting for other factors. This analysis examined the association between discrimination and VMS and the extent to which discrimination accounts for the disproportionate burden of VMS in Black women...
April 9, 2024: Menopause: the Journal of the North American Menopause Society
#23
JOURNAL ARTICLE
Elizabeth Williams, Latesha K Harris, Shuo Zhang, Yamnia I Cortés
OBJECTIVE: This study aimed to evaluate the association between daily spiritual experiences and allostatic load (AL) trajectories in midlife African American women. METHODS: A longitudinal analysis of public-use data from 727 African American women in the Study of Women's Health Across the Nation (SWAN) was performed. We included African American women who completed the Daily Spiritual Experiences Scale at SWAN visit 4 (2000-2001) and had AL data at three or more study visits over 7 years...
April 9, 2024: Menopause: the Journal of the North American Menopause Society
#24
JOURNAL ARTICLE
Meghan Casey, Elissa Dabkowski, Ma Regina L de Gracia, Kathleen A Moore, Gerard A Kennedy, Joanne E Porter, Yasmina Nasstasia, Marlies E Alvarenga
IMPORTANCE: Physical activity during menopause can be effective in reducing the physiological changes associated with reproductive aging that increase risks for noncommunicable diseases, yet many women do not meet the recommendations for physical activity. OBJECTIVE: This study aimed to synthesize factors influencing physical activity for women across menopausal transition phases using a socioecological approach. EVIDENCE REVIEW: The Preferred Reporting Items for Systematic Reviews and Meta-Analysis was used to systematically search 10 databases between 2001 and 2021...
April 9, 2024: Menopause: the Journal of the North American Menopause Society
#25
REVIEW
Paola Villa, Valentina Elisabetta Bounous, Inbal Dona Amar, Federica Bernardini, Margherita Giorgi, Daniela Attianese, Annamaria Ferrero, Marika D'Oria, Giovanni Scambia
BACKGROUND: Advances in the treatment of gynecological cancer have led to improvements in survival but also an increase in menopausal symptoms, especially in young women with premature iatrogenic menopause. METHODS: A narrative review was performed to clarify the possibility of prescribing hormone replacement therapy (HRT) after hormone-dependent gynecological cancers (ovarian cancer [OC], cervical adenocarcinoma [AC], and endometrial cancer [EC]). RESULTS: HRT can be prescribed to patients with early-stage, grade I-II OC who experience bothersome menopausal symptoms non-responsive to alternative non-hormone therapy after optimal surgery...
March 1, 2024: Journal of Clinical Medicine
#26
JOURNAL ARTICLE
Nishanthini Natarajan, Partha Nandi, Narayan Ka, Lokeshmaran S
Introduction Globally, the health of women has been of great concern for healthcare providers for the past many years. However, the concern is limited to maternal and adolescent health and the life course approach is lagging. Thus, a need was felt to study the changes after menopause and its influential factors by determining the prevalence of menopausal symptoms and medico-socio-cultural dimensions of menopause among perimenopausal and early postmenopausal women. Methodology A cross-sectional analytical study was conducted from February 2014 to April 2015 in a rural area of Puducherry among 148 women in perimenopausal and early postmenopausal stages by complete enumeration using a pre-tested semi-structured questionnaire...
March 2024: Curēus
#27
REVIEW
Graziamaria Corbi, Marika Comegna, Caterina Vinciguerra, Alessio Capasso, Luigi Onorato, Alfonso Maria Salucci, Antonio Rapacciuolo, Alessandro Cannavo
Sex differences are consistently identified in determining the prevalence, manifestation, and response to therapies in several systemic disorders, including those affecting the cardiovascular (CV), skeletal muscle, and nervous system. Interestingly, such differences are often more noticeable as we age. For example, premenopausal women experience a lower risk of CV disease than men of the same age. While at an advanced age, with menopause, the risk of cardiovascular diseases and adverse outcomes increases exponentially in women, exceeding that of men...
April 8, 2024: Experimental Gerontology
#28
JOURNAL ARTICLE
Susann Eichler, Mareike Panz, Anastasia Harder, Clarissa Masur, Manuel Häuser, Erik Schulze Zur Wiesche
OBJECTIVES: The efficacy and tolerability of a non-hormonal pessary (that forms an oil-in-water emollient with the vaginal fluid) were assessed for the treatment of symptoms of vaginal dryness associated with menopause. STUDY DESIGN: Seventy-nine postmenopausal women (mean age 60.8 ± 6.5 years) with mild to moderate symptoms of vaginal dryness (including dyspareunia) were enrolled in this open-label, prospective, post-market clinical follow-up trial, conducted in 2022 by one research center in Germany...
March 29, 2024: Maturitas
#29
REVIEW
Mohsen M A Abdelhafez, Karim A M Ahmed, Nashwa A M Ahmed, Mohd H Ismail, Mohd N M Daud, Aya M E Eldiasty, Mohd F B Amri, Mohammad S Jeffree, Fairrul K Masnah, Dg M P Baharuddin, Mohd F Bolong, Mohd F Hayati, Nornazirah B Azizan, Doreen Sumpat, Syed S S Abdul Rahim, Win W Than, Mohd Y Ibrahim, Zhen Z Lo, May Z Soe
Menopausal hormone therapy (MHT) is known to increase the risk of venous thromboembolism (VTE), which includes deep vein thrombosis, pulmonary embolism, and less frequently cerebral vein thrombosis, but the absolute risk for a given patient is very low. After starting MHT, the risk of VTE seems to be at its highest, declining to the non-HRT user baseline level of risk after stopping. Whether estrogen-only or estrogen-progestin HRT combination is linked to a similar risk of VTE is unclear from the available evidence...
March 31, 2024: African Journal of Reproductive Health
#30
JOURNAL ARTICLE
Amal M Elhusein, Hammad A Fadlalmola, Huda H Abedelwahed, Alawìa A Elshaikh, Amel E Banaga, Manal H F Alrahman, Nafesa H Abdelgadim, Insaf H Mohammed, Afaf A A Abdalla, Fatma A M Abdalla, Ebtihag M Abd Allah, Nagwa I Abbas, Abdullah D Alhujaili, Egbal A Almkiy, Eltayeb A Idress, Eltayeb M Awadalkareem, Selwa Y Abdeldafie, Prema Balusamy, Rasha A Mohamed, Rami S M Aloufi, Mohammed Habiballa, Mohammed A Abdelmalik, Mohammed M Alhejaili, Ibrahim A Ibrahim, Huda K Masaad
Menopause represents the physiological transition when a woman's reproductive period ends associated with a variety of symptoms, including vasomotor symptoms, such as night sweats and hot flashes. This systematic review and meta-analysis aimed to assess the effectiveness and safety of oral Fezolinetant for treating vasomotor symptoms associated with menopause. Five electronic databases were searched from their inception until May 2023. Via the Cochrane risk of bias tool, two reviewers assessed the studies' quality...
March 31, 2024: African Journal of Reproductive Health
#31
REVIEW
Nancy Safwan, Mariam Saadedine, Chrisandra L Shufelt, Ekta Kapoor, Juliana M Kling, Rajeev Chaudhry, Stephanie S Faubion
INTRODUCTION: Menopause is a natural part of a woman's life that coincides with a time when many women play significant roles in the workforce. Menopause symptoms, such as hot flashes, fatigue, and difficulty with concentration and memory, can have a negative effect on work productivity and efficiency. OBJECTIVES: This paper summarizes the impact of menopause in the workplace, with an emphasis on the impact of symptoms on employed women and how the workplace influences their experiences...
April 3, 2024: Maturitas
#32
Anwar Rjoop, Rawan Obiedat, Ayat Al-Oqaily, Shaden Abu Baker, Ismail Matalka
This article reports a case of an ovarian collision tumour consisting of an ovarian fibroma and a serous cystadenoma. A 60-year-old woman exhibited symptoms of post-menopausal bleeding and abdominal pain persisting for three months. Computerized tomography identified a solid mass with a cystic component in the right adnexa, and the patient underwent staging laparotomy. Gross examination of the right ovary revealed a cystic tumour with adjacent solid mass. The histopathological analysis identified a cystic mass that matched the characteristics of a serous cystadenoma, with an adjacent solid mass that matched the characteristics of a sex-cord stromal tumour, both located in the right ovary...
June 2024: Case Reports in Women's Health
#33
JOURNAL ARTICLE
Cortney Crespo, Deborah Erlich
No abstract text is available yet for this article.
March 2024: American Family Physician
#34
JOURNAL ARTICLE
Aslınur Albayrak, Kayhan Nuri Cengiz
BACKGROUND: Female breast cancer is the most frequently diagnosed cancer, and knowledge of breast cancer risk factors, and symptoms is crucial for early diagnosis and prevention. This study aims to evaluate breast cancer awareness among female students at a pharmacy faculty in Turkey. METHODS: A cross-sectional online survey study was conducted among female students at the Suleyman Demirel University Faculty of Pharmacy between 2 November and 17 November 2023, in Isparta, Turkey...
April 3, 2024: BMC Medical Education
#35
JOURNAL ARTICLE
Amy Y Lee, Anna T Lyons, Vaia Makris, Sailaja Kamaraju, Melinda R Stolley, Joan M Neuner, Kathryn E Flynn
PURPOSE: Oral adjuvant endocrine therapy (AET) is an effective treatment for hormone receptor positive breast cancer to decrease recurrence and mortality, but adherence is poor. This study explored post-menopausal women's experiences with AET, with a particular focus on adherence to AET as well as distress and symptoms experienced prior to and during AET treatment. METHODS: Participants were recruited from a hospital registry, stratified by adherence to/discontinuation of AET...
April 2, 2024: Supportive Care in Cancer
#36
JOURNAL ARTICLE
JoAnn V Pinkerton, James Simon, Nick Panay, Christian Seitz, Susanne Parke, Cecilia Caetano, Uwe Mellinger, Nazanin Haseli Mashhadi, Claudia Haberland, Gordana Atanackovic, Cornelia Holz, Guangping Mao, Marina Morrison, Sven Nisius, Matthias Schaefers, Lineke Zuurman
OBJECTIVE: Elinzanetant is a selective neurokinin-1,3 receptor antagonist in development for the treatment of vasomotor symptoms (VMS) associated with menopause. The pivotal, double-blind, randomized, placebo-controlled phase 3 studies Overall Assessment of efficacy and Safety of elinzanetant In patients with vasomotor Symptoms (OASIS) 1 and 2 will assess the efficacy and safety of elinzanetant in women with VMS. METHODS: The OASIS 1 and 2 pivotal studies are designed in accordance with regulatory guidance...
April 3, 2024: Menopause: the Journal of the North American Menopause Society
#37
REVIEW
Panagiotis Anagnostis, Konstantinos Lallas, Anna Pappa, Georgios Avgeris, Kristina Beta, Dimitrios Damakis, Eirini Fountoukidou, Maria Zidrou, Irene Lambrinoudaki, Dimitrios G Goulis
BACKGROUND/AIMS: Vasomotor symptoms (VMS) adversely affect postmenopausal quality of life. However, their association with bone health has not been elucidated. This study aimed to systematically review and meta-analyze the evidence regarding the association of VMS with fracture risk and bone mineral density (BMD) in peri- and postmenopausal women. METHODS: A literature search was conducted in PubMed, Scopus and Cochrane databases until 31 August 2023. Fracture, low BMD (osteoporosis/osteopenia) and mean change in lumbar spine (LS) and femoral neck (FN) BMD were assessed...
April 2, 2024: Osteoporosis International
#38
REVIEW
Syed Muhammad Muneeb Akhtar, Abraish Ali, Muhammad Sohaib Khan, Vareesha Khan, Areeba Fareed, Syed Zia Saleem, Munazza Mumtaz, Muhammad Nadeem Ahsan, Sadia Iqbal, Muhammad Sohaib Asghar
BACKGROUND: Vasomotor symptoms (VMS), such as hot flashes and night sweats, are highly prevalent and burdensome for women experiencing menopausal transition. Fezolinetant, a selective neurokinin 3 receptor (NK3R) antagonist, is a potential therapeutic option for mitigating VMS. OBJECTIVES: Our aim is to assess the efficacy and evaluate the safety profile of fezolinetant compared with placebo in post-menopausal women suffering from VMS, by pooling all the relevant data and reflecting the most current evidence...
April 2, 2024: International Journal of Gynaecology and Obstetrics
#39
JOURNAL ARTICLE
Danny Salazar-Pousada, Valeria Ortega-Uscocovich, Cecibel Ramírez-Morán, Peter Chedraui
OBJECTIVE: To assess menopausal symptoms and determine awareness of menopausal related information in mid-aged women. METHODS: This was a cross-sectional study in which 140 women aged 40 to 60 years from Guayaquil, Ecuador were surveyed with the short 10-item Cervantes Scale (CS-10) and a questionnaire containing personal data and questions assessing awareness of menopause related information. RESULTS: The mean age of the sample was 48...
December 2024: Gynecological Endocrinology
#40
JOURNAL ARTICLE
Yu Tian, Yi Lin, Conghui Qu, Volker Arndt, James W Baurley, Sonja I Berndt, Stephanie A Bien, D Timothy Bishop, Hermann Brenner, Daniel D Buchanan, Arif Budiarto, Peter T Campbell, Robert Carreras-Torres, Graham Casey, Andrew T Chan, Rui Chen, Xuechen Chen, David V Conti, Virginia Díez-Obrero, Niki Dimou, David A Drew, Jane C Figueiredo, Steven Gallinger, Graham G Giles, Stephen B Gruber, Marc J Gunter, Sophia Harlid, Tabitha A Harrison, Akihisa Hidaka, Michael Hoffmeister, Jeroen R Huyghe, Mark A Jenkins, Kristina M Jordahl, Amit D Joshi, Temitope O Keku, Eric Kawaguchi, Andre E Kim, Anshul Kundaje, Susanna C Larsson, Loic Le Marchand, Juan Pablo Lewinger, Li Li, Victor Moreno, John Morrison, Neil Murphy, Hongmei Nan, Rami Nassir, Polly A Newcomb, Mireia Obón-Santacana, Shuji Ogino, Jennifer Ose, Bens Pardamean, Andrew J Pellatt, Anita R Peoples, Elizabeth A Platz, John D Potter, Ross L Prentice, Gad Rennert, Edward A Ruiz-Narvaez, Lori C Sakoda, Robert E Schoen, Anna Shcherbina, Mariana C Stern, Yu-Ru Su, Stephen N Thibodeau, Duncan C Thomas, Konstantinos K Tsilidis, Franzel J B van Duijnhoven, Bethany Van Guelpen, Kala Visvanathan, Emily White, Alicja Wolk, Michael O Woods, Anna H Wu, Ulrike Peters, W James Gauderman, Li Hsu, Jenny Chang-Claude
BACKGROUND: Menopausal hormone therapy (MHT), a common treatment to relieve symptoms of menopause, is associated with a lower risk of colorectal cancer (CRC). To inform CRC risk prediction and MHT risk-benefit assessment, we aimed to evaluate the joint association of a polygenic risk score (PRS) for CRC and MHT on CRC risk. METHODS: We used data from 28,486 postmenopausal women (11,519 cases and 16,967 controls) of European descent. A PRS based on 141 CRC-associated genetic variants was modeled as a categorical variable in quartiles...
April 1, 2024: British Journal of Cancer
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
